Fingerprint
Dive into the research topics of 'Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, Neil Senzer, Robert L. Coleman, John Nemunaitis
Research output: Contribution to journal › Article › peer-review
2
Scopus
citations